Literature DB >> 35419738

Melatonin Attenuates Inflammation, Oxidative Stress, and DNA Damage in Mice with Nonalcoholic Steatohepatitis Induced by a Methionine- and Choline-Deficient Diet.

Fabiano Moraes Miguel1,2, Jaqueline Nascimento Picada3, Juliana Bondan da Silva1, Elizângela Gonçalves Schemitt2, Josieli Raskopf Colares2, Renata Minuzzo Hartmann2, Cláudio Augusto Marroni4, Norma Possa Marroni2,5.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a disease with a high incidence worldwide, but its diagnosis and treatment are poorly managed. In this study, NASH pathophysiology and DNA damage biomarkers were investigated in mice with NASH treated and untreated with melatonin (MLT). C57BL/6 mice were fed a methionine- and choline-deficient (MCD) diet for 4 weeks to develop NASH. Melatonin was administered at 20 mg/kg during the last 2 weeks. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were measured, and hepatic tissue was dissected for histological analysis, evaluation of lipoperoxidation, superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as nuclear factor-erythroid 2 (Nrf2), tumor necrosis factor alpha (TNF-α), inducible nitric oxide synthase (iNOS), and transforming growth factor beta (TGF-β) expression by immunohistochemistry. DNA damage was evaluated using Comet assay, while a micronucleus test in bone marrow was performed to assess the genomic instability associated with the disease. Melatonin decreased AST and ALT, liver inflammatory processes, balloonization, and fibrosis in mice with NASH, decreasing TNF-α, iNOS, and TGF-β, as well as oxidative stress, shown by reducing lipoperoxidation and intensifying Nrf2 expression. The SOD and GPx activities were increased, while CAT was decreased by treatment with MLT. Although the micronucleus frequency was not increased in mice with NASH, a protective effect on DNA was observed with MLT treatment in blood and liver tissues using Comet assay. As conclusions, MLT slows down the progression of NASH, reducing hepatic oxidative stress and inflammatory processes, inhibiting DNA damage via anti-inflammatory and antioxidant actions.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  DNA damage; cytokines; melatonin; mutagenicity; nonalcoholic steatohepatitis, oxidative stress.

Year:  2022        PMID: 35419738     DOI: 10.1007/s10753-022-01667-4

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.657


  47 in total

1.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

2.  Melatonin mitigates thioacetamide-induced hepatic fibrosis via antioxidant activity and modulation of proinflammatory cytokines and fibrogenic genes.

Authors:  Mohamed A Lebda; Kadry M Sadek; Tarek K Abouzed; Hossam G Tohamy; Yasser S El-Sayed
Journal:  Life Sci       Date:  2017-11-24       Impact factor: 5.037

Review 3.  Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease.

Authors:  Cynthia Lebeaupin; Deborah Vallée; Younis Hazari; Claudio Hetz; Eric Chevet; Béatrice Bailly-Maitre
Journal:  J Hepatol       Date:  2018-06-27       Impact factor: 25.083

Review 4.  Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.

Authors:  Vignan Manne; Priya Handa; Kris V Kowdley
Journal:  Clin Liver Dis       Date:  2017-10-18       Impact factor: 6.126

Review 5.  Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Omar Massoud; Michael Charlton
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

Review 6.  Non-alcoholic fatty liver disease - A global public health perspective.

Authors:  Zobair M Younossi
Journal:  J Hepatol       Date:  2018-11-09       Impact factor: 25.083

Review 7.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Authors:  Zobair Younossi; Frank Tacke; Marco Arrese; Barjesh Chander Sharma; Ibrahim Mostafa; Elisabetta Bugianesi; Vincent Wai-Sun Wong; Yusuf Yilmaz; Jacob George; Jiangao Fan; Miriam B Vos
Journal:  Hepatology       Date:  2019-06       Impact factor: 17.425

Review 8.  Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.

Authors:  Kenneth Cusi
Journal:  Diabetologia       Date:  2016-04-21       Impact factor: 10.122

9.  Phase angle and non-alcoholic fatty liver disease before and after bariatric surgery.

Authors:  Joise Teixeira; Cláudio Augusto Marroni; Paula Rosales Zubiaurre; Ana Henz; Lais Faina; Lilian Kethelyn Pinheiro; Claudio Cora Mottin; Sabrina Alves Fernandes
Journal:  World J Hepatol       Date:  2020-11-27

10.  Melatonin modulates red-ox state and decreases viability of rat pancreatic stellate cells.

Authors:  Antonio Gonzalez; Matias Estaras; Salome Martinez-Morcillo; Remigio Martinez; Alfredo García; Mario Estévez; Patricia Santofimia-Castaño; Jose A Tapia; Noelia Moreno; Marcos Pérez-López; María P Míguez; Gerardo Blanco-Fernández; Diego Lopez-Guerra; Miguel Fernandez-Bermejo; Jose M Mateos; Daniel Vara; Vicente Roncero; Gines M Salido
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.